Diabetic Kidney Disease (DKD) Models
Ace Therapeutics delivers a comprehensive suite of diabetic kidney disease (DKD) models and preclinical services designed to accelerate compound profiling and biomarker discovery. Leveraging multiple rodent systems—from chemically induced hyperglycemia to genetically predisposed strains—our platform supports mechanistic studies, efficacy screening and translational biomarker development to inform clinical decisions.
Diabetic kidney disease, a leading cause of chronic kidney failure, involves complex interactions between metabolic dysregulation, glomerular hyperfiltration, and progressive fibrosis. Translational preclinical models must recapitulate these hallmarks to ensure clinically meaningful outcomes. Our platforms address the following research needs:
Our DKD platform combines disease modeling with advanced analytical workflows to deliver actionable insights:
We offer a suite of established models tailored to study distinct phases of DKD, from early hyperfiltration to late-stage fibrosis. Each model undergoes rigorous validation to ensure reproducibility and alignment with human pathophysiology.
| Model Name | Key Features | Primary Applications |
| Streptozotocin (STZ)-induced fibrosis | Progressive albuminuria, glomerulosclerosis, tubulointerstitial fibrosis | Testing antifibrotic agents, metabolic modulators |
| db/db mice + ReninAAV/UNx acceleration | Accelerated renal injury via AAV-mediated renin overexpression + uninephrectomy Evaluating | RAS-targeted therapies, podocyte-protective compounds |
| ZSF1 obese rat metabolic nephropathy | Diabetic nephropathy with obesity, hypertension, and insulin resistance | Assessing metabolic syndrome-linked renal damage, combination therapies |
| High-fat diet (HFD) + low-dose STZ | Type 2 diabetes phenotype with advanced glomerular lesions | Screening agents targeting oxidative stress or lipid metabolism |
All models are validated through histopathological, functional, and molecular endpoints:
Our DKD models support diverse preclinical objectives:
What distinguishes Ace Therapeutics' DKD models from standard approaches?
Our models emphasize clinically relevant progression, such as transitioning from hyperfiltration to fibrosis. For example, the STZ-accelerated model includes longitudinal monitoring of both metabolic and renal parameters.
Can you integrate secondary comorbidities like hypertension?
Yes. The ZSF1 rat model inherently develops hypertension, while other models can be adapted with angiotensin II infusion or salt-sensitive diets.
What endpoints are measured in efficacy studies?
Standard endpoints include UACR, histopathology scoring, and molecular pathway activation. Custom endpoints (e.g., single-nucleus RNA sequencing) are available upon request.
How do you validate model reproducibility?
All models undergo multi-cohort validation with internal controls. Consistency checks include baseline metabolic parameters and injury marker concordance.
Do you offer pharmacokinetic (PK) or safety assessments?
Yes. We provide integrated PK/PD studies with renal tissue distribution analysis and off-target effect screening.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics has a group of highly committed and skilled researchers with the objective to provide innovative preclinical contract research solutions to cope with kidney diseases.
We strives to accelerate the development of innovative therapies that address unmet medical needs.